TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2
Advanced Science · 2026
DOI: 10.1002/advs.202521337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Risheng Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Beihua University, Jilin, Jilin, P. R. China. Hauptthemen laut MEDLINE: Cardiomegaly, Heart Failure, Ubiquitin-Protein Ligases, Tripartite Motif Proteins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jilin Provincial Department of Science and Technology, National Natural Science Foundation of China.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Pathological cardiac hypertrophy is a major predisposing factor for heart failure (HF). This study investigates the role of the E3 ubiquitin ligase Tripartite Motif‐Containing 40 (TRIM40) in cardiac hypertrophy. Using TRIM40 knockout (TRIM40 −/− ), cardiac‐specific knockdown and overexpressing mice, pathological hypertrophy was induced by angiotensin II (Ang II) infusion or transverse aortic constriction (TAC). Results showed that TRIM40 expression was upregulated in hypertrophic hearts. TRIM40 deficiency attenuated cardiac hypertrophy and dysfunction, whereas its overexpression exacerbated pathological remodeling. Mechanistically, TRIM40 binds PKN2 via its B‐box domain and, in a manner requiring its C29‐dependent E3 ligase activity, promotes K63‐linked ubiquitination of PKN2. This leads to enhanced PKN2 phosphorylation at Ser815 and activation of downstream signaling. Pharmacological inhibition of PKN2 attenuated cardiac remodeling induced by TRIM40 overexpression. These findings reveal that TRIM40 drives cardiac hypertrophy through K63‐linked ubiquitination and activation of PKN2, identifying TRIM40 as a promising candidate for therapeutic intervention in HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, Beihua University, Jilin, Jilin, P. R. China.
- Peking University People's Hospital, Qingdao; Women and Children's Hospital, Qingdao University, Qingdao, P. R. China.
- Department of Ultrasonography, Integrated Traditional Chinese and Western Medicine Hospital of Jilin City Jilin Province, Jilin, P. R. China.
ORCID-Profile: Mengyang Wang
Förderung
- Natural Science Foundation of Jilin Provincial Department of Science and Technology
- National Natural Science Foundation of China
Zitieren
APA
Zhao, R., Cui, X., Du, H., Wang, Z., Liu, C., Zhang, L., Qi, J., Yang, D., Yu, H., Yan, S., Liu, W., Sun, H., & Wang, M. (2026). TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2. Advanced Science. https://doi.org/10.1002/advs.202521337
Vancouver
Zhao R, Cui X, Du H, Wang Z, Liu C, Zhang L, et al. TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2. Advanced Science. 2026. doi:10.1002/advs.202521337
BibTeX
@article{Zhao2026,
author = {Zhao, Risheng and Cui, Xiaoli and Du, Huizhu and Wang, Zhuoqun and Liu, Chang and Zhang, Linxin and Qi, Jianing and Yang, Di and Yu, Hui and Yan, Shuang and Liu, Wei and Sun, Haiming and Wang, Mengyang},
title = {TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202521337}
}
EUVIMED